Dyne Therapeutics

Dilution score: 18/100 (LOW), 24.0 months cash

Short interest: 12.74% of float, squeeze risk: MODERATE

Simultaneous Determination of Four Per- and Polyfluoroalkyl Substances (PFAS) in DHA Products using LC-MS/MS for Quality Control and Risk Assessment.

Extraction, development, and ex-vivo evaluation of thermoresponsive mucoadhesive in-situ nasal gel incorporating Lablab purpureus mucilage and Pluronic F127 for enhanced intranasal delivery of Diclofenac Sodium.

Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial.

Development and Evaluation of an In Situ Nasal Gel Formulation of Desloratadine.

Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled study.

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dys

Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1

Efficacy and Tolerance Study of B-DYN Versus Conventional Fusion in the Treatment of Lumbar Stenosis on the Degree of Po

Cardiovascular Research in EMbarazo and MAternity (EMMA). Study on Heart Rate Variability and Hemodynamic Adaptations Du

Calculating Wall Shear Stress in Infant Pulmonary Veins

Dilution score: 36/100 (MEDIUM), 39.9 months cash

Patient reported outcome measures in spinal muscular atrophy and duchenne muscular dystrophy: review of instruments and their inclusion in clinical and regulatory processes.

Short interest: 12.59% of float, squeeze risk: MODERATE

"Extraction, Development, and Ex-Vivo Evaluation of Thermoresponsive Mucoadhesive In-Situ Nasal Gel Incorporating Lablab purpureus Mucilage and Pluronic F127 for Enhanced Intranasal Delivery of Diclofenac Sodium".

Short interest: 12.58% of float, squeeze risk: MODERATE

SW convergence: 50/100 (Neutral), 0 bullish / 1 bearish signals

Dilution score: 36/100 (MEDIUM), 51.2 months cash

Short interest: 12.6% of float, squeeze risk: MODERATE

Short interest: 13.19% of float, squeeze risk: MODERATE

High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.

SW convergence: 55/100 (Neutral), 1 bullish / 2 bearish signals

Short interest: 13.9% of float, squeeze risk: MODERATE

Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial.

<article class="bts-verified-summary" data-ticker="DYN">
<p>Dyne Therapeutics (DYN) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov<sup><a href="#fn-3">[3]</a></sup>, including 2 Phase 2<sup><a href="#fn-1">[1]</a></sup>, 2 Phase 1<sup><a href="#fn-2">[2]</a></sup>.</p>
<p>DYN has 4 Form 4 insider filings recorded at the SEC in the past 30 days<sup><a href="#fn-4">[4]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Dyne+Therapeutics%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-2">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Dyne+Therapeutics%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-3">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Dyne+Therapeutics%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-4">SEC EDGAR · 0001818794 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22DYN%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

ClinicalTrials.gov

SEC EDGAR — 0001818794

Dyne Therapeutics (DYN) — BioTechSigns Verified Summary

Dyne Therapeutics (DYN) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov[3], including 2 Phase 2[1], 2 Phase 1[2].

DYN has 4 Form 4 insider filings recorded at the SEC in the past 30 days[4].

Sources:
[1] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Dyne+Therapeutics%22&aggFilters=status%3Arec%2Cact
[2] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Dyne+Therapeutics%22&aggFilters=status%3Arec%2Cact
[3] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Dyne+Therapeutics%22&aggFilters=status%3Arec%2Cact
[4] SEC EDGAR, 0001818794. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22DYN%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11

The primary purpose of the study is to evaluate the safety and tolerability of multiple intravenous (IV) doses of DYNE-101 administered to participants with Myotonic Dystrophy Type 1 (DM1).

The study consists of 4 periods: A Screening Period (up to 8 weeks), a Placebo-Controlled Period (24 weeks), a Treatment Period (24 weeks) and a Long-Term Extension (LTE) Period (168 weeks) in both multiple-ascending dose (MAD) and dose expansion cohorts.

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1

The primary purpose of this study is to evaluate the safety, tolerability, and dystrophin protein levels in muscle tissue following multiple intravenous (IV) doses of DYNE-251 in participants with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping.

The study consists of 3 periods: a multiple-ascending dose (MAD) / placebo-controlled period (24 weeks), an open-label period (24 weeks) and a long-term extension (LTE) period (192 weeks).

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping